Beximco Pharmaceuticals Limited, IFIC Bank Limited and its Nepalese subsidiary Nepal Bangladesh Bank have donated 5,000 vials of Remdesivir Injection (Bemsivir) to Nepal Government for treating hospitalized COVID-19 patients.
The medicine was handed over today to Ambassador of Nepal to Bangladesh Dr Banshidhar Mishra in a ceremony held at his office, said a press release.
High officials from Beximco Pharma and IFIC Bank were present and spoke on this occasion.
Managing Director of Beximco Pharmaceuticals Nazmul Hassan MP said “We
are committed to doing our best to respond to the COVID-19 pandemic and have proactively manufactured latest and evidence based treatment options for the COVID-19 patients. Donation of Remdesivir to Nepal reinforces our commitment to play our part in ensuring access to breakthrough therapies for patients around the world during this unprecedented pandemic”.
Managing Director of IFIC Bank Shah A Sarwar said, “We are pleased to extend our support to the government of Nepal in its fight against COVID-19 pandemic. As the COVID-19 crisis deepens, we believe access to Remdesivir would greatly help in treating the critically ill COVID-19 patients. We have been operating in Nepal for more than 25 years and, as always, we want to reiterate our strong commitment to standing by our close neighbor in this difficult time.”
Beximco Pharma became the first in the world to launch generic Remdesivir (under the brand “Bemsivir”) upon receiving an emergency use approval from DGDA on May 21, 2020. The antiviral drug, originally developed by US based Gilead Sciences Inc., is supplied by Beximco Pharma under the brand name of Bemsivir.
The company has also supplied this drug to several countries for saving lives of critically ill patients on a humanitarian ground.
Beximco has been providing the drug free of cost to the government designated COVID-19 hospitals in Bangladesh from the very beginning.